Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Antibodies, Monoclonal/*immunology ; Antibodies, Viral/*immunology ; COVID-19/*pathology ; COVID-19 Vaccines/*immunology ; SARS-CoV-2/*immunology; Antibodies, Neutralizing/immunology ; Antibodies, Viral/blood ; COVID-19/therapy ; COVID-19/virology ; Databases, Factual ; Humans ; Immunization, Passive ; Neutralization Tests ; SARS-CoV-2/isolation & purification ; SARS-CoV-2/metabolism ; Spike Glycoprotein, Coronavirus/immunology ; COVID-19 Serotherapy

Competing Interests: R.W.S. has received grant funding from Janssen Pharmaceuticals, Vela Diagnostics and Insilixa; and honoraria from Gilead Sciences and GlaxoSmithKline (GSK). This does not alter our adherence to PLOS ONE policies on sharing data and materials.
As novel SARS-CoV-2 variants with different patterns of spike protein mutations have emerged, the susceptibility of these variants to neutralization by antibodies has been rapidly assessed. However, neutralization data are generated using different approaches and are scattered across different publications making it difficult for these data to be located and synthesized. The Stanford Coronavirus Resistance Database (CoV-RDB; https://covdb.stanford.edu) is designed to house comprehensively curated published data on the neutralizing susceptibility of SARS-CoV-2 variants and spike mutations to monoclonal antibodies (mAbs), convalescent plasma (CP), and vaccinee plasma (VP). As of December 31, 2021, CoV-RDB encompassed 257 publications including 91 (35%) containing 9,070 neutralizing mAb susceptibility results, 131 (51%) containing 16,773 neutralizing CP susceptibility results, and 178 (69%) containing 33,540 neutralizing VP results. The database also records which spike mutations are selected during in vitro passage of SARS-CoV-2 in the presence of mAbs and which emerge in persons receiving mAbs as treatment. The CoV-RDB interface interactively displays neutralizing susceptibility data at different levels of granularity by filtering and/or aggregating query results according to one or more experimental conditions. The CoV-RDB website provides a companion sequence analysis program that outputs information about mutations present in a submitted sequence and that also assists users in determining the appropriate mutation-detection thresholds for identifying non-consensus amino acids. The most recent data underlying the CoV-RDB can be downloaded in its entirety from a GitHub repository in a documented machine-readable format.

Science. 2021 Feb 19;371(6531):850-854. (PMID: 33495308)
Nat Protoc. 2021 Mar;16(3):1761-1784. (PMID: 33514944)
Nature. 2021 Feb;590(7847):630-634. (PMID: 33276369)
Lancet. 2021 Apr 10;397(10282):1347-1348. (PMID: 33770519)
Sci Rep. 2021 Dec 14;11(1):23921. (PMID: 34907214)
Nat Protoc. 2020 Nov;15(11):3699-3715. (PMID: 32978602)
Nat Med. 2021 Nov;27(11):2032-2040. (PMID: 34588689)
Curr Protoc Immunol. 2020 Dec;131(1):e116. (PMID: 33215858)
Science. 2020 Mar 13;367(6483):1260-1263. (PMID: 32075877)
J Exp Med. 2020 Nov 2;217(11):. (PMID: 32692348)
Clin Infect Dis. 2022 Mar 1;74(4):734-742. (PMID: 34302458)
Nat Rev Microbiol. 2021 Jul;19(7):409-424. (PMID: 34075212)
PLoS Negl Trop Dis. 2021 Jul 8;15(7):e0009551. (PMID: 34237072)
Cell. 2020 Apr 16;181(2):281-292.e6. (PMID: 32155444)
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6. (PMID: 33592168)
Nat Rev Genet. 2021 Dec;22(12):757-773. (PMID: 34535792)
Nat Med. 2021 Dec;27(12):2127-2135. (PMID: 34650248)
Nat Commun. 2021 Oct 6;12(1):5861. (PMID: 34615860)
N Engl J Med. 2021 Dec 9;385(24):e84. (PMID: 34614326)
N Engl J Med. 2021 Feb 11;384(6):533-540. (PMID: 33369366)
JCI Insight. 2020 Oct 2;5(19):. (PMID: 32870820)
Nat Biotechnol. 2020 Sep;38(9):1073-1078. (PMID: 32704169)
Nature. 2020 May;581(7807):221-224. (PMID: 32225175)
PLoS One. 2020 Feb 26;15(2):e0225352. (PMID: 32102090)
Cell. 2020 Sep 3;182(5):1295-1310.e20. (PMID: 32841599)
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9. (PMID: 33259788)
Nat Med. 2021 Jul;27(7):1205-1211. (PMID: 34002089)
Sci Transl Med. 2021 Jun 30;13(600):. (PMID: 34103407)
J Clin Microbiol. 2021 Sep 20;59(10):e0052721. (PMID: 34288726)
Cell Rep Med. 2021 Apr 20;2(4):100255. (PMID: 33842902)
BMJ. 2021 Dec 15;375:e068848. (PMID: 34911691)
Viruses. 2020 Sep 09;12(9):. (PMID: 32916958)
Nat Commun. 2021 Jul 7;12(1):4196. (PMID: 34234131)
Bioinformatics. 2018 Sep 15;34(18):3094-3100. (PMID: 29750242)
Vaccine. 2021 Jul 22;39(32):4423-4428. (PMID: 34210573)
Sci Adv. 2021 Jul 30;7(31):. (PMID: 34330709)
Nucleic Acids Res. 2003 Jan 1;31(1):298-303. (PMID: 12520007)
PLoS Pathog. 2022 Feb 8;18(2):e1010248. (PMID: 35134084)
Viruses. 2020 May 06;12(5):. (PMID: 32384820)
Nature. 2020 May;581(7807):215-220. (PMID: 32225176)

R24 AI136618 United States AI NIAID NIH HHS

0 (Antibodies, Monoclonal)
0 (Antibodies, Neutralizing)
0 (Antibodies, Viral)
0 (COVID-19 Vaccines)
0 (Spike Glycoprotein, Coronavirus)
0 (spike protein, SARS-CoV-2)

SARS-CoV-2 variants

Date Created: 20220309 Date Completed: 20220317 Latest Revision: 20221207

20250114

PMC8906623

10.1371/journal.pone.0261045

35263335